Unaprime buys Tata Healthcare's 43.5% in Lokmanya Hospitals

Lokmanya Hospitals has five hospitals located in Pune, Pimpri-Chinchwad and Kolhapur. The hospitals have an existing capacity of 300 beds and plan to expand to 500 beds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OiGIPZq
via IFTTT

Read More

Zydus gets Mexican regulatory approval to market cancer treatment product

The product is used in the treatment of breast cancer and advanced gastric cancer. Breast cancer has become the most diagnosed cancer in Mexico, overtaking prostate and colorectal cancers, the company added. Developed in-house by the research team at the Zydus Research Centre (ZRC), the Trastuzumab biosimilar was launched in 2016 in India under the brand name Vivitra. Since then, an estimated 1 lakh patients have been treated with the therapy, the company added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oJMvAZG
via IFTTT

Read More

Heavy metal in most chocolates may not pose health risk, researchers say

Some consumer groups and independent test agencies have previously reported heavy metal contamination in cocoa products such as dark chocolate, with possible causes being the type of soil where cocoa is grown and industrial processing. Researchers at the George Washington University School of Medicine and ConsumerLab.com found that 70 of the 72 cocoa-containing products they analyzed fell below limits set by the Food and Drug Administration (FDA) for lead contamination.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S65bq1T
via IFTTT

Read More

TA Associates, 2 others offer to buy into Eye Foundation

TA Associates, Multiples PE, and KKR have made non-binding offers to invest ₹830 crore for a 25% stake in Eye Foundation, valuing it at ₹3,360 crore. With an expected EBITDA of ₹140 crore for FY25, the eye care chain's asset-light, scalable model is drawing substantial private equity interest.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NpDboAt
via IFTTT

Read More

Govt plans crackdown on lookalike drug brands

According to people in the know, the government is likely to consider as valid only the brand names which were approved first by the regulator. Other same or similar sounding and lookalike brands will not be allowed to be marketed. Drug makers will soon be asked to upload formulation details along with the brand names of their products on the government's portal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QW0kRu4
via IFTTT

Read More

Drug MNCs for keeping patient aid plan out of trade margin formula

The Organisation of Pharmaceutical Producers of India (OPPI) recommended excluding Patient Assistance Programmes (PAPs) from Trade Margin Rationalisation to maintain affordability for patients. They noted that PAPs are crucial for providing access to expensive drugs, especially for oncology and rare diseases. OPPI also sought exemption for patented and orphan drugs from government-set price controls and opposed post-patent price cuts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7szSUgu
via IFTTT

Read More

Narrative claiming vapes, e-cigarettes healthier alternatives are misleading: Experts

Experts have raised concerns about the portrayal of e-cigarettes as healthier alternatives to tobacco, warning they can lead to traditional tobacco use among youth. India's ban on these products has potentially prevented millions of addictions. Public awareness and stringent regulations were emphasized as necessary to tackle this issue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SUOu9z2
via IFTTT

Read More

Cipla expects to commence supplies to US from China plant later this year

Cipla plans to start supplying from its China facility to the US market by the second half of the current fiscal year, following USFDA approval. The company is resolving regulatory issues with its domestic plants and focusing on new therapeutic areas and tech-based solutions. Cipla is also addressing antimicrobial resistance and expanding its digital health initiatives.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pvuqdyt
via IFTTT

Read More

Mankind Pharma taps Barclays and Deutsche Bank for Rs 13,630 cr acquisition of Bharat Serums & Vaccines

Mankind Pharma has appointed Barclays and Deutsche Bank to arrange financing for its Rs 13,630 crore acquisition of Bharat Serums & Vaccines. The deal will be partly funded through Rs 4,000 crore in internal accruals and the rest via debt. Mankind’s board approved raising ₹7,500 crore in equity and increasing the borrowing limit to ₹12,500 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Xr74ZfY
via IFTTT

Read More

Textiles and pharma PLI schemes likely to see longer product list

The cabinet was set to decide on expanding the production-linked incentive (PLI) schemes in sectors like textiles, food processing, and pharmaceuticals to include more products. Meanwhile, the budget for PLI schemes increased to `16,092 crore for FY25. Textile PLI might see a lower investment threshold, with more man-made fabric products and apparel possibly being added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/31ANVRe
via IFTTT

Read More

Mankind to use debt, internal accruals to fund BSV buyout

Mankind Pharma announced a ₹13,630 crore acquisition of Bharat Serums and Vaccines (BSV) to be funded through internal accruals and a mix of debt and equity. This strategic move will make them leaders in the gynaecology-fertility segment. The acquisition aligns with their goal to expand in high-potential areas and is expected to boost earnings from the second year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kS16e2Z
via IFTTT

Read More

Sun Pharma's drug to treat alopecia areata gets USFDA nod

Sun Pharmaceutical Industries Ltd announced that the USFDA has approved its drug LEQSELVI (deuruxolitinib) for treating adults with severe alopecia areata. The approval is based on Phase 3 clinical trials involving 1,220 patients. LEQSELVI provides a new treatment option for patients with significant hair loss due to this autoimmune disorder.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i9NwTQc
via IFTTT

Read More

General Atlantic, other PE funds in talks for majority stake in AIMS

General Atlantic and KKR are among several private equity firms vying for a majority stake in Faridabad-based Asian Institute of Medical Sciences (AIMS), valued at approximately ₹1,500 crore. Other interested parties include Growtheum Capital and Everstone Capital, while IndiaRF has withdrawn from the bidding.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0ul8Avn
via IFTTT

Read More

Mankind Pharma to acquire Bharat Serums from Advent International for Rs 13,630 cr

Mankind Pharma announced its acquisition of Bharat Serums and Vaccines Limited (BSV) from Advent International for approximately Rs 13,630 crore. This deal positions Mankind Pharma as a leader in the Indian women's health and fertility drug market, expanding its portfolio to include high-entry barrier products in critical care with established R&D technology platforms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ac7FyeD
via IFTTT

Read More

Diabetes management in the time of urbanisation: An Indian perspective

India's rapid urbanisation and economic growth have led to a spike in chronic diseases, including diabetes, particularly in rural areas. Increased disposable income, sedentary lifestyles, and unhealthy eating habits are driving this trend. Addressing these health challenges requires a consistent approach prioritising early detection, balanced diets, and education on diabetes management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QCKaDGf
via IFTTT

Read More

Mankind Pharma is frontrunner in Bharat Serums bid

Mankind Pharma is in talks to acquire Bharat Serums & Vaccines Ltd., a biopharmaceutical company with brands like Manforce Condoms and Prega News pregnancy tests. The target company could be valued at around $1.5 billion. Advent International, which acquired a majority stake in Bharat Serums in 2019, is looking to exit and return liquidity to investors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i5WhXza
via IFTTT

Read More

Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement

Mayne Pharma sued India's Sun Pharma for allegedly infringing patents on IMVEXXY, a drug for menopause-related vaginal pain. The lawsuit was filed after Sun Pharma sought FDA approval for a generic version. This action might delay FDA approval for Sun Pharma by 30 months under the Hatch-Waxman Act.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VMJpB8b
via IFTTT

Read More

Experts say a twice-yearly injection that offers 100% protection against HIV is 'stunning'

The shots made by U.S. drugmaker Gilead and sold as Sunlenca are approved in the U.S., Canada, Europe and elsewhere, but only as a treatment for HIV. The company said it is waiting for results of testing in men before seeking permission to use it to protect against infection.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1YQGMuj
via IFTTT

Read More

Budget 2024: Cancer patients get relief but senior citizens missed the attention

The Union Budget 2024, while significantly increasing health sector funding to ₹90,959 crore, failed to address the BJP’s poll promise of including senior citizens above 70 in Ayushman Bharat-PMJAY. The budget features customs duty exemptions for three cancer drugs and changes to basic customs duty for X-ray equipment. Reactions from healthcare leaders underscore the budget's focus on improving accessibility and infrastructure. However, the omission of the senior citizens' health cover highlights a key unfulfilled promise, leaving a gap in comprehensive healthcare improvements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OZ2rMTY
via IFTTT

Read More

Govt mulls dropping quality tests for cough syrups from developed market-approved plants

The proposal, which follows a representation from a stakeholder, suggests that testing at the prescribed laboratory may be waived for cough syrups being exported to the US, UK, Canada, EU, Japan, Australia, Singapore, Republic of Korea and Switzerland.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vAmWe7I
via IFTTT

Read More

Drugs regulatory body may waive testing requirement for cough syrups exported to certain countries

CDSCO mulls exempting cough syrups from testing before export to select countries. Quality concerns arose last year prompting mandatory testing. Stakeholders seek waiver, while data shows some batches failed quality standards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/INBWwY6
via IFTTT

Read More

Budget 2024: Government proposes to fully exempt 3 cancer drugs from customs duty

The government proposes to cut custom duties on Trastuzumab Deruxtecan, Osimertinib and Durvalumab from 10 per cent to nil. Finance Minister Nirmala Sitharaman also proposed changes in the basic customs duty (BCD) on x-ray tubes and flat panel detectors for use in medical x-ray machines under the phased manufacturing programme, so as to synchronise them with domestic capacity addition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GMXNxVQ
via IFTTT

Read More

Economic Survey: Mental health issues rising, holistic approach required

The Economic Survey highlights the increase in mental health issues in India, emphasizing the need for a community-based approach. Urban areas show higher prevalence than rural areas. Health expenditure has grown significantly. AB PM-JAY scheme estimated to save over 1.25 lakh crore for disadvantaged families.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5EYjbXe
via IFTTT

Read More

Over 100 cough syrup makers fail quality test

A government report reveals that over 100 pharma units' cough syrup samples failed quality tests, showing the same toxins linked to child deaths in Gambia, Uzbekistan, and Cameroon. The Central Drugs Standard Control Organisation's analysis found 353 out of 7,087 batches sub-standard,. Issues include unsecured supply chains and inadequate testing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l9KkEIq
via IFTTT

Read More

Next leg of pharma sector growth necessitates skill advancement, innovation: Eco Survey

Economic Survey 2024: The domestic pharmaceutical industry in India needs skill advancement, innovation, and a robust supply chain to meet the expected segment size of USD 130 billion by 2030, according to the Economic Survey 2023-24 tabled in Parliament on Monday. Currently, the Indian pharmaceutical market is valued at around USD 50 billion, making it the world's third-largest by volume.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QWh2IU0
via IFTTT

Read More

Sanofi initiates voluntary recall of Allegra, Combiflam suspensions due to contamination in some batches

Sanofi has announced a "temporary halt" on the sales of Allegra Suspension and Combiflam Suspension in India, due to microbiological contamination. The precautionary recall, affecting specific batches, aims to ensure safety while investigations continue. These medicines, commonly used for treating allergies and pain in children, are being recalled from distributors, hospitals, and retailers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NDdXI9r
via IFTTT

Read More

Pharma MNCs seek relief from price control for patented drugs

The Organisation of Pharmaceutical Producers of India (OPPI) is requesting exemptions for patented and orphan drugs from government price controls. They argue that current regulations hinder innovation and want more control over pricing post-patent expiry to provide economic incentives for inventors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dmMxwFP
via IFTTT

Read More

Kerala: 14-year-old dies from Nipah virus; causes, symptoms, and treatment explained

Amid the rising concerns over the spread of the virus, listed below are the causes, symptoms and treatment:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UFehr9k
via IFTTT

Read More

Budget FY25: Pharmaceuticals sector needs a major boost with increased focus on R&D and innovation

The Union Budget 2024-2025, pivotal for India's Amrit Kaal vision, aims to foster economic growth and inclusive development. The budget is expected to boost infrastructure, streamline bureaucracy, and promote technology and innovation. Emphasis on the pharmaceutical sector, with increased allocations, can drive India's economic and healthcare advancements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x8HpKwZ
via IFTTT

Read More

CCI approves two acquisitions involving Arjas Steel, Suven Pharmaceutical

The Competition Commission of India (CCI) has approved two major acquisitions involving Arjas Steel Private Limited (ASPL) and its wholly owned subsidiary, Arjas Modern Steel Private Limited (AMSPL). The acquisition will be carried out indirectly by The Sandur Manganese & Iron Ores Limited (SMIORE) and BAG Holdings Private Limited (BHPL), as per an official statement by CCI.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1AbtFnZ
via IFTTT

Read More

Dr Reddy's inks licensing pact with Takeda to sell gastrointestinal drug

New Delhi: Dr Reddy's Laboratories, a Hyderabad-based firm, and Takeda Pharmaceutical entered a non-exclusive licensing pact to market 10mg and 20mg Vonoprazan tablets, a PCAB for reflux esophagitis and acid peptic disorders, in India. CEO MV Ramana highlighted the strategic collaboration. Shares rose 0.33% to Rs 6,665.10 on BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wtplLcq
via IFTTT

Read More

USFDA classifies Zydus Lifesciences Jarod unit as 'official action indicated'

Zydus Lifesciences Ltd has been classified as "official action indicated" by the US Food and Drug Administration (FDA) for its Jarod injectables manufacturing facility in Gujarat. The FDA's inspection, conducted between April 15 and 23, 2024, suggests the facility may withhold approval for pending product applications or supplements until outstanding observations are resolved.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8hj1TuK
via IFTTT

Read More

SC dismisses Sun Pharma's plea against NPPA's demand notice of Rs 4.65 cr for overcharging drug

The Supreme Court dismissed Sun Pharma's plea against a demand notice of Rs 4.65 crore by NPPA for overcharging for the drug Roscilox, upholding the Delhi High Court's decision. Sun Pharma challenged the demand for overcharged amount under DPCO, with the court finding no merit in the appeal. It noted Sun Pharma's direct purchase from the manufacturer and overlapping identities with Oscar Laboratories Pvt. Ltd.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KNJj1cU
via IFTTT

Read More

Sanofi looking to expand India hub with Rs 3.6k-cr push

The Hyderabad GCC will support Sanofi's global operations spanning commercial, manufacturing, supply chain research and development (R&D) and digitalisation. The GCC in India will help the company bring some of outsourced functions in-house, giving it more control over critical operations like manufacturing, commercial and R&D.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NYW2Ldg
via IFTTT

Read More

USFDA approves Glenmark Pharma's seizure treatment drug

New Delhi-based Glenmark's USFDA-approved 15 mg and 25 mg Topiramate capsules, equivalent to Janssen's Topamax, will be marketed by Glenmark Pharmaceuticals Inc., USA. Topamax had recorded annual sales worth USD 21.9 million per IQVIATM (till May 2024). Glenmark's US portfolio has 198 products, 50 ANDAs pending, and seeks growth through external development partnerships.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y83YDJS
via IFTTT

Read More

Mankind Pharma competes with EQT-ADIA combo for Rs 14,000 cr buyout of BSV Group from Advent

The buyout of BSV Group (formerly Bharat Serum & Vaccines Ltd) is contested by Mankind Pharma and EQT with ADIA, each offering around Rs 14,000 crore ($1.6 billion). This acquisition, one of India's largest pharma buyouts, will significantly impact the domestic market and mark a successful exit for Advent International.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cOQgE4K
via IFTTT

Read More

Pharma companies against plan to bring nutraceuticals under drug regulator

Controversy arises as government considers shifting nutraceuticals to drug regulatory authority from FSSAI oversight. Industry experts express reservations and call for detailed discussions. Nutraceutical segment set to reach $18 billion in India by 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f4SrmWX
via IFTTT

Read More

Cipla gets Rs 773 crore demand notice from I-T department

The additional demand was raised for disallowances related to deduction of profits and gains derived from the business of developing, maintaining, and operating the infrastructure facilities, expenditure on R&D, business or professional expenses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/n8exAop
via IFTTT

Read More

Mankind Pharma in licensing pact with Takeda to market acidity drug Vonoprazan in India

Mankind Pharma partners with Takeda to introduce Vonoprazan for GERD, oesophagitis, ulcers, and Helicobacter pylori in India. EVP Ramesh stresses business growth. Collaborations with AstraZeneca (Symbicort) and Novartis (Neptaz) enhance their strategy. In-licensing, including royalties on sales, expands domestic formulations using local sales networks, improving access to innovative therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7TPOpaE
via IFTTT

Read More

Supreme Court upholds NPPA's Rs 4.65 cr recovery from Sun Pharma for drug price violation

The Supreme Court upheld NPPA's Rs 4.65 crore recovery from Sun Pharma for Roscilox overpricing (April 1996 - July 2003). The appeal was rejected owing to inconsistencies and Paragraph 13 of DPCO. Delhi HC found overlap with Oscar Laboratories. Sun Pharma, acting as dealer and distributor, lacked documentation, with direct contact as per DPCO definitions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yFgX2Bj
via IFTTT

Read More

Lupin divests women's health specialty business in US to Evofem Biosciences for nearly $84 mn

Lupin announced the sale of its US commercial women’s health specialty business, focusing on Solosec, to Evofem Biosciences. Solosec, an FDA-approved single-dose treatment for bacterial vaginosis and trichomoniasis, is the key product involved. The deal includes potential payments up to USD 84 million based on future milestones.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d1Gyk7c
via IFTTT

Read More

Diabetes and heart disease: A call for integrated management

Statistics show low treatment target compliance among Indian diabetes patients, increasing heart disease risks. Timely screening and weight management are crucial for better health outcomes. Learn more about the importance of integrated management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qZ4frMo
via IFTTT

Read More

Pharma industry seeks relief from price cap rule for cheap drugs

India’s FoPE seeks a 10-year exemption for patented and low-cost drugs from price controls. Requests include DPCO and 12% GST adjustments due to 15-130% ingredient cost rises. Presenting to the DoP secretary, FoPE cites working capital issues prompting overseas research. Supported by IPA, Harish Jain stressed necessary revisions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/C51tja2
via IFTTT

Read More

Top 5 tips to prevent hair loss in monsoon

Here are five tips to prevent hair loss during the monsoon season:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wcQRsKN
via IFTTT

Read More

Gel polish, acrylic nails: How a booming industry can cause cancer

Nail art, acrylic nails and gel manicures are becoming increasingly popular, with celebrities including Kylie Jenner, Ariana Grande and Rihanna often donning them.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lGHhx7X
via IFTTT

Read More

Nutraceuticals may get cheaper as panel looks to regulate prices

The Indian government is contemplating bringing nutraceuticals under price control to enhance affordability for consumers. Currently regulated by the Food Safety and Standards Authority of India (FSSAI) without price controls, these products, often marketed as over-the-counter health supplements, face scrutiny for high pricing. Officials argue that some companies charge exorbitant prices by repackaging pharmaceutical ingredients into nutraceuticals. A committee involving various health and regulatory bodies aims to introduce pricing regulations to curb this trend and ensure fair pricing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y6fzRPi
via IFTTT

Read More

MGM Healthcare promoter acquires Vizag's SevenHills Hospital under IBC

The Amravati bench at Mangalagiri of the National Company Law Tribunal approved a ₹171 crore resolution plan against ₹1,361.89 crore admitted claims from creditors, employees, and others. The secured creditors admitted claim was ₹1,273 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/10SbTEY
via IFTTT

Read More

Indian pharma companies faked generic viagra data to gain approval, finds US FDA

FDA's June 18 alert revealed falsified data by Synapse Labs affecting generics like Umedica's Viagra. Europe had earlier warned. Insurers might change coverage. Both Massoud Motamed and Erin Fox highlight ingredient risks. Due to confidentiality, FDA hasn't disclosed all affected drugs, suspended sales, or done significant public outreach. Identified generics include Lupin's Lipitor and Aurobindo's risendronate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IlKyAWv
via IFTTT

Read More

Zydus barred from selling cancer biosimilar, for now

The Delhi High Court has temporarily barred Zydus Lifesciences from selling its breast cancer drug Sigrima, a biosimilar of Roche's Perjeta (pertuzumab), due to a patent infringement lawsuit filed by Roche. The court granted an interim injunction against Zydus after Roche argued that Sigrima and another biosimilar, Womab from Dr Reddy's, violate its patents. Zydus had received conditional approval for its pertuzumab biosimilar but launched it amidst ongoing litigation, prompting the court to intervene to prevent potential market disruption.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xIOGgFJ
via IFTTT

Read More

From napkin scribbles to heart pumps, a life-saving breakthrough from casual dinner talk

An Indian surgeon and Australian professor founded Cardiobionic to create affordable heart pumps. Patented prototypes, including a bi-ventricular assist pump, use a non-contact impeller and are undergoing animal tests. Cardiobionic has been funded by Indian investors and others

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5eMz2K0
via IFTTT

Read More

GSK gets restraining order against Elder Laboratories

GSK approached the high court against Elder Laboratories early this year for alleged infringement of trademark, including usage of identical product names, trademarks and packaging. GSK issued several notices to Elder before approaching the court seeking a restraining order.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/irDu2XQ
via IFTTT

Read More

Maharashtra government to bring new law to crack down on bogus pathology labs

The issue concerns the urban development, public health and medical education departments, Samant said. BJP MLA Ashish Shelar said bogus pathology labs were looting money and playing with people's lives. Several collection centres that have come up over the years should be registered, he said, demanding criminal cases against violators.

from Healthcare/Biotech-Industry-Economic Times https://economictimes.indiatimes.com/industry/healthcare/biotech/maharashtra-government-to-bring-new-law-to-crack-down-on-bogus-pathology-labs/articleshow/111600846.cms
via IFTTT

Read More

5 veggie superfoods to boost collagen naturally

Including these veggies in your diet can help maintain healthy skin and support your body’s natural collagen production:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iPgODHf
via IFTTT

Read More

Budget 2024: Is a Rs 10 lakh insurance the vitamin India's healthcare system needs?

The Centre is considering doubling the beneficiary base of the Ayushman Bharat health insurance scheme over the next three years, starting with those aged above 70, alongside raising annual coverage to Rs 10 lakh. These proposals are anticipated in the upcoming Union Budget. The interim Budget increased Ayushman Bharat's allocation to Rs 7,200 crore for secondary and tertiary care, with Rs 646 crore for health infrastructure.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/04ziwtk
via IFTTT

Read More

As monsoon sets in, respiratory, malaria drugs see demand rise

The onset of the monsoon in June led to a significant increase in sales of drugs for respiratory, anti-infective, anti-malaria, and gastrointestinal therapies. According to market researcher Pharmarack, these therapies saw double-digit growth compared to June 2023.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/w0zjDOL
via IFTTT

Read More

Budget 2024: Pharma sector seeks tax sops, effective intellectual property rights regime

Union Budget: Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wVlRUab
via IFTTT

Read More

Apollo Hospitals to acquire Rs 103.2 crore stake in subsidiary Apollo Health

"... we wish to inform you that the Company is acquiring 35,12,107 equity shares of Rs 10 each at a price of Rs.294/- per share (including premium of Rs.284/- per share) aggregating to Rs. 1032.60 million by way of subscribing to the rights issue of Apollo Health and Lifestyle Limited, a subsidiary of the Company (AHLL)," the hospital chain company informed stock exchanges on Saturday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Gu98tAS
via IFTTT

Read More

Budget 2024: Drugmakers want Nirmala Sitharaman to prescribe tax relief tablet for the economy

Budget 2024: Indian pharmaceutical companies are looking for tax incentives and financial support in the upcoming Union Budget to boost research on innovative drugs. Industry experts emphasize the importance of thinking creatively and implementing policies to enhance growth in the sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OChbBjz
via IFTTT

Read More

Drugs body flags side effects of heart, Glaucoma medications

The Indian Pharmacopoeia Commission has issued a drug safety alert regarding amlodipine and acetazolamide, highlighting potential adverse reactions. Healthcare professionals are advised to monitor for adverse drug reactions, while patients should be vigilant for any symptoms. Companies may be required to include warnings in drug packaging.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KGPc1kX
via IFTTT

Read More

Fortis designates Prem Kumar Nair as Vice-Chairman

He was appointed Group Chief Executive Officer of IHH Healthcare on October 1, 2023.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J5bECL2
via IFTTT

Read More

Nutrition advocacy NAPi calls for amending regulations for ads of unhealthy foods

Consequences of such advertising are increased intake of unhealthy food products associated with obesity and diabetes, the report said. “India is facing a dubious distinction of persistent under-nutrition among children under five, and a rising trend of obesity and diabetes among grown-ups,” according to the report.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IW2Q6qx
via IFTTT

Read More

Cancer risk and diet: Foods to be cautious about

Certain foods and dietary habits have been associated with an increased risk of cancer. To reduce cancer risk, it is recommended to follow a diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats, while limiting the intake of the foods and drinks listed above. Here are some examples:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8Io51yC
via IFTTT

Read More

Need to sensitise foreign nationals on organ transplant guidelines in India: Health ministry

"It is essential for these foreign nationals visiting India for organ transplant to understand the specific guidelines and legal requirements that regulate the process of organ transplantation in India," Chandra said in the letter addressed to Union Home Secretary Ajay Kumar Bhalla and Union Foreign Secretary Vinay Mohan Kwatra on June 19.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kWHyn0P
via IFTTT

Read More

Inclusive healthcare: H.E. Dr. Noura Khamis Al Ghaithi on Abu Dhabi’s vision beyond borders

In conversation with H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, who outlines the vision of the Abu Dhabi Global Healthcare Week (ADGHW) positioned to serve as an annual platform for inclusive knowledge-sharing and crafting collaborative strategies aimed at delivering positive patient outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VTLs2jE
via IFTTT

Read More

Zydus Lifesciences gets tentative approval from USFDA for BP lowering drug

Zydus Lifesciences announced on Thursday that it has received tentative approval from the US Food and Drug Administration (USFDA) to market its generic Azilsartan Medoxomil tablets, which are used to treat high blood pressure. The USFDA's tentative approval covers Azilsartan Medoxomil tablets in strengths of 40 mg and 80 mg.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zzsh1ad
via IFTTT

Read More

Waiting for a wonder drug? The weight just got longer

Eli Lilly awaits India's approval to sell Tirzepatide, marketed as Mounjaro and Zepbound in the US. CEO David Ricks plans to launch the drug in India in 2025, pending supply. The SEC recommends approval for pre-filled pens and vials, contingent on a phase-IV trial. The Drug Controller General of India will finalize the decision.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DhvRGUm
via IFTTT

Read More

Warning letter: USFDA pulls up Sun Pharma for manufacturing issues at Dadra facility

"Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitise and/or sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements," the USFDA said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IT1PXKa
via IFTTT

Read More

Living with diabetes: A holistic approach

Combatting diabetes through weight loss is key for reducing risks of heart disease and stroke, emphasizing holistic lifestyle management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qsQ6JwA
via IFTTT

Read More

Weekly-once insulin jab may soon come to India

A new weekly insulin dosage by Novo Nordisk, Insulin Icodec, is on the brink of approval in India, offering potential relief for those who require daily insulin injections. The Subject Expert Committee has recommended permitting the import and sale of this innovative product, expected to revolutionise the insulin market. While further studies are required, doctors anticipate improved patient compliance with this new treatment option.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/It8Biyn
via IFTTT

Read More

Zika virus spreads in Pune: Here's how the virus infects, risks, symptoms, and prevention

Pune faces a rising Zika virus threat with six recent cases, including two pregnant women. Health authorities are intensifying surveillance and mosquito control efforts. Zika, transmitted by Aedes mosquitoes, poses significant risks during pregnancy, potentially leading to severe birth defects. While symptoms are usually mild, caution is advised, especially for expectant mothers. Here’s a comprehensive overview of Zika virus infection, its symptoms, impact on pregnancy, and preventive measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4p0C9nc
via IFTTT

Read More

Understanding Dengue: What is dengue? Symptoms and treatment; Can dengue kill?

Dengue fever is a mosquito-borne viral infection prevalent in tropical and subtropical regions worldwide, including India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d8iYCzW
via IFTTT

Read More

KKR set to acquire Kerala's Baby Memorial Hospitals, make a comeback in hospital segment

KKR & Co plans to acquire a 70% stake in Kerala's Baby Memorial Hospital (BMH) for $300 million, marking its return to the Indian hospital sector. BMH, with 500 beds and expansion plans, is among Kerala’s largest hospitals. This move aligns with KKR’s strategy of expanding healthcare assets in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sOSWHxV
via IFTTT

Read More